An Early Clinical Evaluation of Clopenthixol in Treatment-Resistant Female Schizophrenic Patients
ARTHUR WOLPERT M.D., PH.D.1,
CHARLES SHEPPARD M.A.1, , and
SIDNEY MERLIS M.D.1
1 Research Division, Central Islip State Hospital, Central Islip, N. Y. 11722
Some published results from the European literature regarding the therapeutic and untoward effects of clopenthixol therapy were replicated. Therapeutic response was demonstrated at a daily dosage of 50 mg. An initial drowsiness was noted within a few days of therapy. No laboratory abnormalities were noted.
The global impressions of the ward physician were confirmed by the statistical evaluation of the rating data. A significant improvement was demonstrated in this sample of treatment-resistant, chronic female schizophrenics. This has encouraged us to formulate a further, more extensive investigation of clopenthixol in a larger double-blind comparative study.
